Premium
Local Fas/APO‐1 (CD95) ligand‐mediated tumor cell killing in vivo
Author(s) -
RensingEhl Anne,
Frei Karl,
Flury Renata,
Matiba Bernd,
Mariani Sara M.,
Weller Michael,
Aebischer Patrick,
Krammer Peter H.,
Fontana Adriano
Publication year - 1995
Publication title -
european journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 201
eISSN - 1521-4141
pISSN - 0014-2980
DOI - 10.1002/eji.1830250821
Subject(s) - biology , in vivo , fas receptor , fas ligand , ligand (biochemistry) , microbiology and biotechnology , apoptosis , cell , cancer research , programmed cell death , receptor , genetics
Abstract Fas/APO‐1 (CD95) is a cell surface receptor which mediates apoptosis when ligated by specific antibodies or by its recently cloned natural ligand, FasL. We have studied the cytotoxic potential of FasL in vivo using Fas/APO‐1‐expressing Yac‐1 cells as targets. Supernatant harvested from Neuro‐2a cells transfected with the murine FasL cDNA contains FasL and transduces a potent apoptotic signal to Yac‐1 cells in vitro . Specificity of FasL‐mediated cytotoxicity was confirmed by competition assays using soluble Fas or anti‐Fas/APO‐1 F(ab') 2 fragments which specifically interfere with FasL‐Fas/APO‐1 interactions. Intraperitoneal injection of FasL‐containing supernatant efficiently killed Yac‐1 target cells which had been implanted in capsules into the peritoneal cavity of mice. Analysis of the target cells revealed DNA fragmentation and nuclear changes typical of apoptosis. As previously shown, intraperitoneal injection of anti‐Fas/APO‐1 antibodies caused liver failure (Ogasawara, J., Watanabe, F. R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T. and Nagata, S., Nature 1993. 364 : 806) and was observed at doses which did not reduce Yac‐1 cell viability. In contrast, FasL did not induce histopathology in the liver when applied intraperitoneally at doses cytotoxic for Yac‐1 cells. However, intravenous administration of FasL induced lethal liver hemorrhages and hepatocyte apoptosis. Thus, locally applied FasL kills tumor cells very efficiently without systemic toxicity and may therefore represent a candidate for local tumor treatment.